BCMA-specific TAC receptor-engineered T cells for multiple myeloma

      Recent clinical trials with B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T cells have demonstrated susceptibility of relapsed and/or refractory multiple myeloma to treatment with engineered T cells. To provide engineered T cells with a natural way of auto-regulating their activity, we designed a novel chimeric receptor, called the T cell antigen coupler (TAC). TAC redirects endogenous T cell receptor to the target of interest to engage natural T cell activation mechanisms. Herein, we discuss our results with a series of BCMA TAC receptors and reveal that TAC T cells are biologically distinct from CAR T cells.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect